Mirati Therapeutics

Mirati Therapeutics is a clinical-stage biotechnology company based in San Diego, dedicated to advancing novel therapies to extend the lives of patients by directly addressing the genetic and immune drivers of cancer. Mirati Therapeutics is involved in the development of Sitravatinib, a spectrum-selective kinase inhibitor currently in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC); as well as a Phase Ib clinical trial for NSCLC patients with Casitas B-lineage lymphoma gene alterations, and a KRAS G12C inhibitor program for patients with NSCLC adenocarcinoma, colorectal cancer, and other cancers.